Oral administration versus injectable administration for the fluoroquinolones. Pharmacoeconomic impact and bibliographical study;INTERET DE L'UTILISATION DE LA VOIE ORALE PAR RAPPORT A LA VOIE INJECTABLE POUR LES FLUOROQUINOLONES. INCIDENCE PHARMACOECONOMIQUE ET ETUDE BIBLIOGRAPHIQUE

Therapie

Volumn 51, Issue 4, 1996, Pages 464-475

  Douet, C ^a   Charpiat, B ^a   Peyramond, D ^a   Brazier, J L ^b  

^a CROIX ROUSSE HOSPITAL   (France)

^b Institut des Sciences Pharmaceutiques et Biologiques   (France)

Author keywords

Administration; Fluoroquinolone; Pharmacoeconomy; Pharmacokinetic

Indexed keywords

CIPROFLOXACIN; OFLOXACIN; PEFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; ANTIINFECTIVE AGENT; QUINOLONE DERIVATIVE;

BIOEQUIVALENCE; CONFERENCE PAPER; DATA ANALYSIS; DRUG ADMINISTRATION; DRUG COST; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; ORAL DRUG ADMINISTRATION; PHARMACOECONOMICS; PRIORITY JOURNAL; ECONOMICS; PHARMACOKINETICS; REVIEW;

ADMINISTRATION, ORAL; ANTI-INFECTIVE AGENTS; FLUOROQUINOLONES; HUMANS; INJECTIONS, INTRAVENOUS; THERAPEUTIC EQUIVALENCY;

EID: 0029740249     PISSN: 00405957     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (115)

1. Douet C, Kroener S, Traore A et al. Indicateurs économiques de choix de la voie d'administration des fluoroquinolones. J Pharm Clin 1994; 13: 97-101.
2. Gleckman R, Gantz NM. Cost effective antibiotic prescribing. Pharmacotherapy 1983; 3: 239-248.
3. Guglielmo BJ, Brooks GF. Antimicrobial therapy. Cost benefit considerations. Drugs 1989; 38 : 473-480.
4. Noorby SR. Consumption of antibiotics in Sweden, 1975 to 1992. Pharmacoeconomic and clinical aspects. Pharmaco Economics 1992; 2 : 238-244.
5. Powers T, Bingham DH. Clinical and economic effect of ciprofloxacin as an alternative to injectable antimicrobial therapy. Am J Hosp Pharm 1990; 47: 1781-1784.
6. Lederle FA, Parenti CM, Berskow LC, Ellingson KJ. The idle intravenous catheter. Ann Intern Med 1992; 116: 737-738.
7. Bergan T, Thorsteinsson SB, Kolstad IM, Johnsen S. Pharmacokinetics of ciprofloxacin after intravenous and increasing oral doses. Eur J Clin Microbiol 1986; 5: 187-192.
8. Bergan T, Thorsteinsson SB, Solberg R et al. Pharmacokinetics of ciprofloxacin: intravenous and increasing oral doses. Am J Med 1987; 82 (Suppl 4A): 97-102.
9. Borner K, Hoffken G, Lode H et al. Pharmacokinetics of ciprofloxacin in healthy volunteers after oral and intravenous administration. Eur J Clin Microbiol 1986; 5: 179-186.
10. Brumfitt W, Franklin I, Grady D et al. Changes in the pharmacokinetics of ciprofloxacin and fecal flora during administration of a 7-day course to human volunteers. Antimicrob Agents Chemother 1984; 26: 757-761.
11. Dan M, Poch F, Quassem C, Kitzes R. Pharmacokinetic-bactericidal correlations after a single 200mg IV dose of ciprofloxacin. Drugs 1993; 45 (Suppl 3): 242-243.
12. Davis RL, Koup JR, Williams-Warren J et al. Pharmacokinetics of three oral formulations of ciprofloxacin. Antimicrob Agents Chemother 1985; 28: 74-77.
13. Davis RL, Koup JR, Williams-Warren J et al. Pharmacokinetics of ciprofloxacin in cystic fibrosis. Antimicrob Agents Chemother 1987; 31: 915-919.
14. Follath F, Bindschedler M, Wenk M et al. Use of ciprofloxacin in the treatment of Pseudomonas aeruginosa infections. Eur J Clin Microbiol 1986; 5: 236-240.
15. Fourtillan JB. Caractéristiques pharmacocinétiques de la ciprofloxacine par voies orale et intraveineuse. Med Mal Inf 1990; 20: 33-37.
16. Hoffken G, Lode H, Prinzing C et al. Pharmacokinetics of ciprofloxacin after oral and parenteral administration. Antimicrob Agents Chemother 1985; 27: 375-379.
17. Lebel M, Barbeau G, Bergeron MG et al. Pharmacokinetics of ciprofloxacin in elderly subjects. Pharmacotherapy 1986; 6: 87-91.
18. Lebel M, Bergeron MG, Vallee F et al. Pharmacokinetics and pharmacodynamics of ciprofloxacin in cystic fibrosis patients. Antimicrob Agents Chemother 1986; 30: 260-266.
19. Lettieri JT, Rogge MC, Kaiser L et al. Pharmacokinetic profiles of ciprofloxacin after single intravenous and oral doses. Antimicrob Agents Chemother 1992; 36: 993-996.
20. Lettieri JT, Kaiser L, Krol G, Heller AH. Comparative pharmacokinetics of oral and intravenous ciprofloxacin. Drugs 1993; 45 (Suppl 3): 271-272.
21. Lettieri JT, Rogge MC, Echols R et al. Pharmacokinetics of ciprofloxacin after single oral and intravenous doses. Drugs 1993; 45 (Suppl 3): 273-274.
22. Lode H, Hoffken G, Olschewski P et al. Comparative pharmacokinetics of intravenous ofloxacin and ciprofloxacin. J Antimicrob Chemother 1988; 22 (Suppl C): 73-79.
23. Naber KG, Sorgel F, Kees F et al. Pharmacokinetics of ciprofloxacin in young (healthy volunteers) and elderly patients, and concentrations in prostatic fluid, seminal fluid, and prostatic adenoma tissue following intravenous administration. Am J Med 1989; 87 (Suppl 5A): 57-59.
24. Nix DE, Spivey JM, Norman A, Schentag JJ. Dose-ranging pharmacokinetic study of ciprofloxacin after 200-, 300- and 400-mg intravenous doses. Ann Pharmacother 1992; 26: 8-10.
25. Peloquin CA , Cumbo TJ, Nix De et al. Evaluation of intravenous ciprofloxacin in patients with nosocomial lower respiratory tract infections. Impact of plasma concentrations, organism, minimum inhibitory concentration, and clinical condition on bacterial eradication. Arch Intern Med 1989; 149: 2269-2273.
26. Stutman HR, Shalit I, Marks MI et al. Pharmacokinetics of two dosage regimens of ciprofloxacin during a two-week therapeutic trial in patients with cystic fibrosis. Am J Med 1987; 82 (Suppl 4A): 142-145.
27. Tartaglione TA, Raffalovich AC, Poynor WJ et al. Pharmacokinetics and tolerance of ciprofloxacin after sequential increasing oral doses. Antimicrob Agents Chemother 1986; 29: 62-66.
28. Trenholme GM, Schmitt BA, Spear J et al. Randomized study of intravenous/oral ciprofloxacin versus ceftazidime in the treatment of hospital and nursing home patients with lower respiratory tract infections. Am J Med 1989; 87 (Suppl 5A): 116-118.
29. Ullmann U, Giebel W, Dalhoff A , Koeppe P. Single and multiple dose pharmacokinetics of ciprofloxacin. Eur J Clin Microbiol 1986; 5: 193-196.
30. Ball AP, Fox C, Ball ME et al. Pharmacokinetics of oral ciprofloxacin, 100 mg single dose, in volunteers and elderly patients. J Antimicrob Chemother 1986; 17: 629-635.
31. Bergan T, Thorteinsson SB, Kolstad IM, Johnsen S. Pharmacokinetics of ciprofloxacin after intravenous and increasing oral doses. Eur J Clin Microbiol 1986; 5: 187-192.
32. Borner K, Lode H, Hoffken G et al. Comparative pharmacokinetics of ofloxacin and ciprofloxacin. Rev Inf Dis 1988; 10 (Suppl 1): 91.
33. Crump B, Wise R, Dent J. Pharmacokinetics and tissue penetration of ciprofloxacin. Antimicrob Agents Chemother 1983; 24: 784-786.
34. Daly JS, Worthington MG, Razvi SA, Robillard R. Intravenous and sequential intravenous and oral ciprofloxacin in the treatment of severe infections. Am J Med 1989; 87 (Suppl 5A): 232-234.
35. Drusano GL, Plaisance KI, Forrest A, Standiford HC. Dose ranging study and constant infusion evaluation of ciprofloxacin. Antimicrob Agents Chemother 1986; 30: 440-443.
36. Drusano GL, Standiford HC, Plaisance K et al. Absolute oral bioavailability of ciprofloxacin. Antimicrob Agents Chemother 1986; 30: 444-446.
37. Dudley MN, Mandler HD, Gilbert D et al. Pharmacokinetics and pharmacodynamics of intravenous ciprofloxacin. Studies in vivo and in vitro model. Am J Med 1987; 82 (Suppl 4A): 363-368.
38. Garraffo R, Dellamonica P, Bernard E et al. Steady-state serum pharmacokinetics and bioequivalence of 500 mg oral versus 200 mg intravenous ciprofloxacin. Int J Clin Pharm Res 1989; 9: 29-35.
39. Gonzalez MA, Moranchel AH, Duran S et al. Multiple-dose pharmacokinetics of ciprofloxacin administered intravenously to normal volunteers. Antimicrob Agents Chemother 1985; 28: 235-239.
40. Gonzalez MA, Moranchel AH, Duran S et al. Multiple-dose ciprofloxacin dose ranging and kinetics. Clin Pharmacol Ther 1985; 37: 633-637.
41. Gonzalez MA, Uribe F, Duran S et al. Multiple-dose pharmacokinetics and safety of ciprofloxacin in normal volunteers. Antimicrob Agents Chemother 1984; 26: 741-744.
42. Kljucar S, Heimesaat M, Von Pritzbuer E et al. Efficacy and safety of higher-dose intravenous ciprofloxacin in severe hospital-acquired infections. Am J Med 1989; 87 (Suppl 5A): 52-56.
43. Lebel M, Barbeau G, Bergeron MG et al. Pharmacokinetics of ciprofloxacin in elderly subjects. Pharmacotherapy 1986; 6: 87-91.
44. Lebel M, Bergeron MG, Vallee F et al. Pharmacokinetics and pharmacodynamics of ciprofloxacin in cystic fibrosis patients. Antimicrob Agents Chemother 1986; 30: 260-266.
45. Ljungberg B, Nilsson-Ehle I. Pharmacokinetics of intravenous ciprofloxacin at three different doses. J Antimicrob Chemother 1988; 22: 715-720.
46. Neuvonen PJ, Kivisto KT, Lehto P. Interference of dairy products with the absorption of ciprofloxacin. Clin Pharmacol Ther 1991; 50: 498-502.
47. Plaisance KI, Drusano GL, Forrest A et al. Effect of dose size on bioavailability of ciprofloxacin. Antimicrob Agents Chemother 1987; 31: 956-958.
48. Silverman SH, Johnson M, Burdon DW, Keighley MRB. Pharmacokinetics of single dose intravenous ciprofloxacin in patients undergoing gastrointestinal surgery. J Antimicrob Chemother 1986; 18: 107-112.
49. Weinstein MP, Echols RM, Kowalsky SF, Heller AH. Comparative pharmacokinetics and serum bactericidal activities (SBA) of ciprofloxacin (C) and ofloxacin (O) following single dose (oral [PO] and intravenous [IV]) administration. Drugs 1993; 45 (Suppl 3): 472.
50. Wingender W, Beermann D, Forster D, Horstmann R. Steady-state pharmacokinetics of ciprofloxacin in healthy volunteers after intravenous infusion. Rev Inf Dis 1988; 10 (Suppl 1): 93-94.
51. Wingender W, Graefe KH, Gau W et al. Pharmacokinetics of ciprofloxacin after oral and intravenous administration in healthy volunteers. Eur J Clin Microbiol 1984; 3: 355-359.
52. Wise R, Donovan IA. Tissue penetration and metabolism of ciprofloxacin. Am J Med 1987; 82 (Suppl 4A): 103-107.
53. Wise R, Lister D, McNulty CAM et al. The comparative pharmacokinetics of five quinolones. J Antimicrob Chemother 1986; 18 (Suppl D) : 71-81.
54. Wise R, Lockley RM, Webberly M, Dent J. Pharmacokinetics of intravenously administered ciprofloxacin. Antimicrob Agents Chemother 1984; 26: 208-210.
55. Fillastre JP, Leroy A, Humbert G. Ofloxacin pharmacokinetics in renal failure. Antimicrob Agents Chemother 1987; 31: 156-160.
56. Flor S, Beals B. The bioavailability of ofloxacin from several formulations. Curr Med Res Opin 1991; 12: 282-286.
57. Fourtillan JB. Comparaison des profils pharmacocinétiques de la péfloxacine et de l'ofloxacine lors d'administrations répétées chez le sujet sain. J Pharm Clin 1988; 7: 355-362.
58. Hoffler D, Koeppe P. Pharmacokinetics of ofloxacin in healthy subjects and patients with impaired renal function. Drugs 1987; 34 (Suppl 1): 51-55.
59. Leigh DA, Walsh B, Harris K et al. Pharmacokinetics of ofloxacin and the effect on the faecal flora of healthy volunteers. J Antimicrob Chemother 1988; 22 (Suppl C): 115-125.
60. Leroy O, Beuscart C, Sivery B et al. Efficacité et tolérance de l'ofloxacine intraveineuse. Etude multicentrique française chez 273 malades. Presse Med 1989; 18: 2050-2054.
61. Lode H, Hoffken G, Olschewski P et al. Pharmacokinetics of ofloxacin after parenteral and oral administration. Antimicrob Agents Chemother 1987; 31: 1338-1342.
62. Maesen FPV, Davies BI, Baur C, Sumajow CA. Clinical, microbiological and pharmacokinetic studies on ofloxacin in acute purulent exacerbations of chronic respiratory disease. J Antimicrob Chemother 1986; 18: 629-634.
63. Yuk JH, Nightingale CH, Quintiliani R, Sweeney KR. Bioavailability and pharmacokinetics of ofloxacin in healthy volunteers. Antimicrob Agents Chemother 1991; 35: 384-386.
64. Dagrosa EE, Verho M, Malerczyk V et al. Multiple-dose pharmacokinetics of ofloxacin, a new broad-spectrum antimicrobial agent. Clin Ther 1986; 8: 632-645.
65. De Bernardis E, Bonaccorsi S, Carlino S et al. Pharmacokinetics and tissue distribution of ofloxacin in human subjects during a multiple dose regimen. Int J Clin Pharm Res 1988; 8: 239-245.
66. Farinotti R, Trouvin JH, Bocquet V et al. Pharmacokinetics of ofloxacin after single and multiple intravenous infusions in healthy subjects. Antimicrob Agents Chemother 1988; 32: 1590-1592.
67. Graber H, Ludwig E, Arr M, Lanyi P. Pharmacokinetics of ofloxacin in young and elderly patients. Rev Inf Dis 1988; 10 (Suppl 1): 106.
68. Guay DRP, Opsahl JA, McMahon FG et al. Safety and pharmacokinetics of multiple doses of intravenous ofloxacin in healthy volunteers. Antimicrob Agents Chemother 1992; 36: 308-312.
69. Leroy A, Borsa F, Humbert G et al. The pharmacokinetics of ofloxacin in healthy adult male volunteers. Eur J Clin Pharmacol 1987; 31: 629-630.
70. Lockley MR, Wise R, Dent J. The pharmacokinetics and tissue penetration of ofloxacin. J Antimicrob Chemother 1984; 14: 647-652.
71. Marchbanks CR, Dudley MN, Flor S, Beals B. Pharmacokinetics and safety of single rising doses of ofloxacin in healthy volunteers. Pharmacotherapy 1992; 12: 45-49.
72. Okhamafe AO, Akerele JO. Some aspects of the bioavailability of orally administered ofloxacin in healthy human volunteers. Int J Pharmaceutics 1989; 50: 83-86.
73. Verho M, Malerczyk V, Dagrosa E, Korn A. Dose linearity and other pharmacokinetics of ofloxacin: a new, broad-spectrum antimicrobial agent. Pharmatherapeutica 1985; 4: 376-382.
74. Verho M, Malerczyk V, Dagrosa E, Korn A. The effect of food on the pharmacokinetics of ofloxacin. Curr Med Res Opin 1986; 10: 166-171.
75. Warlich R, Korting HC, Schafer-Korting M, Mutschler E. Multiple-dose pharmacokinetics of ofloxacin in serum, saliva, and skin blister fluid of healthy volunteers. Antimicrob Agents Chemother 1990; 34: 78-81.
76. Frydman AM, Le Roux Y, Lefebvre MA et al. Pharmacokinetics of pefloxacin after repeated intravenous and oral administration (400 mg bid) in young healthy volunteers. J Antimicrob Chemother 1986; 17 (Suppl B): 65-79.
77. Sorgel F, Mahr G, Stephan U et al. Absolute bioavailability and pharmacokinetics of pefloxacin in healthy volunteers. Rev Inf Dis 1988; 10 (Suppl 1): 93.
78. Wolf M, Pangon B, Regnier B et al. Traitement de septicémies et endocardites par la péfloxacine. Presse Med 1986; 15: 471-474.
79. Barre J, Houin G, Tillement JP. Dose-dependent pharmacokinetic study of pefloxacin, a new antibacterial agent, in humans. J Pharm Sci 1984; 73: 1379-1382.
80. Griggs D, Lister D, Andrews LM, Wise R. Pharmacokinetics and inflammatory-fluid penetration of pefloxacin. Rev Inf Dis 1988; 10 (Suppl 1): 98.
81. Montay G, Goueffon Y, Roquet F. Absorption, distribution, metabolic fate, and elimination of pefloxacin mesylate in mice, rats, dogs, monkeys, and humans. Antimicrob Agents Chemother 1984; 25: 463-472.
82. Webberley JM, Andrews JM, Ashby JP et al. Pharmacokinetics and tissue penetration of orally administered pefloxacin. Eur J Clin Microbiol 1987; 6: 521-524.
83. Zurcher J, Jaehde U, Gottschalk B et al. Effect of dose on bioavailability, pharmacokinetics and metabolism of pefloxacin following administration of single and multiple doses. Rev Inf Dis 1989; 11 (Suppl 5): 1014-1015.
84. Cardey J, Silvain C, Bouquet S et al. Oral pharmacokinetics and ascitic fluid penetration of pefloxacin in cirrhosis. Eur J Clin Pharmacol 1987; 33: 469-472.
85. Danan G, Montay G, Cunci R, Erlinger S. Pefloxacin kinetics in cirrhosis. Clin Pharmacol Ther 1985; 38: 439-442.
86. Montay G, Gaillot J. Pharmacokinetics of fluoroquinolones in hepatic failure. J Antimicrob Chemother 1990; 26 (Suppl B): 61-67.
87. Bouza E, Diaz-Lopez MD, De Quiros JCLB et al. Ciprofloxacin in patients with bacteremic infections. Am J Med 1989; 87 (Suppl 5A): 228-231.
88. Chrysanthopoulos CJ, Skoutelis AT, Starakis JC et al. Use of intravenous ciprofloxacin in respiratory tract infections and biliary sepsis. Am J Med. 1987; 82 (Suppl 4A): 357-359.
89. Chrysanthopoulos CJ, Starakis JC, Skoutelis AT, Bassaris HP. Sequential intravenous/oral therapy with ciprofloxacin in severe infection. Am J Med 1989; 87 (Suppl 5A): 225-227.
90. Cox CE. Sequential intravenous and oral ciprofloxacin versus intravenous ceftazidime in the treatment of complicated urinary tract infections. Am J Med 1989; 87 (Suppl 5A): 157-159.
91. Gangji D, Jacobs F, De Jonckheer J et al. Randomized study of intravenous versus sequential intravenous/oral regimen of ciprofloxacin in the treatment of Gram-negative septicemia. Am J Med 1989; 87 (Suppl 5A): 206-208.
92. Gelfand MS, Simmons BP, Craft RB, Grogan JT. Clinical study of intravenous and oral ciprofloxacin in complicated bacterial infections. Am J Med 1989; 87 (Suppl 5A): 235-237.
93. Giamarellou H, Galanakis N. Use of intravenous ciprofloxacin in difficult-to-treat infections. Am J Med 1987; 82 (Suppl 4A): 346-351.
94. Greenberg RN, Wilson KM, Brusca PA. Intravenous and oral ciprofloxacin treatment of 52 infections. Am J Med 1989; 87 (Suppl 5A): 238-239.
95. Gudiol F, Cabellos C, Pallares R et al. Intravenous ciprofloxacin therapy in severe infections. Am J Med 1989; 87 (Suppl 5A): 221-224.
96. Modai J. Treatment of serious infections with intravenous ciprofloxacin. Am J Med 1989; 87 (Suppl 5A): 243-247.
97. Neu HC, Davidson S, Briones F. Intravenous/oral ciprofloxacin therapy of infections caused by multiresistant bacteria. Am J Med 1989; 87 (Suppl 5A): 209-212.
98. Peacock JE, Pegram PS, Weber SF, Leone PA. Prospective, randomized comparison of sequential intravenous followed by oral ciprofloxacin with intravenous ceftazidime in the treatment of serious infections. Am J Med 1989; 87 (Suppl 5A): 185-190.
99. Scully BE, Neu HC. Treatment of serious infections with intravenous ciprofloxacin. Am J Med 1987; 82 (Suppl 4A): 369-375.
100. Doco-Lecompte T, Modai J. Efficacité de l'ofloxacine injectable dans le traitement des septicémies - Etude multicentrique. Pathol Biol 1989; 37: 465-467.
101. Mouton Y, Leroy O, Beuscart C et al. Efficacy of intravenous ofloxacin: a French multicentre trial in 185 patients. J Antimicrob Chemother 1990; 26 (Suppl D): 115-121.
102. Presterl E, Teleky B, Winkler S et al. Surgical infections treated parenterally with ofloxacin. Drugs 1993; 45 (Suppl 3): 468-469.
103. Regamey C, Steinbach-Lebbin C. Severe infections treated with intravenous ofloxacin: a prospective clinical multicentre Swiss study. J Antimicrob Chemother 1990; 26 (Suppl D): 107-114.
104. Bernard E, Durant J, Elbaze P, Dellamonica P. Pefloxacin in the treatment of septicaemia: three years' experience. J Antimicrob Chemother 1990; 26 (Suppl B): 97-101.
105. Grassi C, Catena E, De Iola G et al. Pefloxacin in lower respiratory tract infections. J Antimicrob Chemother 1990; 26 (Suppl B): 103-110.
106. Limson BM, Pena AC, Garvez MD. Monotherapy with pefloxacin in multidrug-resistant nosocomial Gram-negative bacteraemia. J Antimicrob Chemother 1990; 26 (Suppl B): 91-95.
107. Balant LP, Gex-Fabry M. Dealing with variability during drug development. J Pharm Pharmacol 1994; 46 (Suppl 1): 439-444.
108. Toon S. Relevance of pharmacokinetic studies in volunteers. Clin Pharmacokinet 1993; 25: 259-262.
109. Forrest A, Ballow CH, Nix De et al. Development of a population pharmacokinetic model and optimal sampling strategies for intravenous ciprofloxacin. Antimicrob Agents Chemother 1993; 37: 1065-1072.
110. Vozeh S. Applications of population approach to clinical pharmacokinetics and validation of the results. In: Rowland M, Aarons L, eds. New strategies in drug development and clinical evaluation: the population approach. Luxenbourg: Office for official publications of the European communities, 1992: 107-124.
111. Tod M, Petitjean O, Nicolas P. Intérêt de la théorie de l'optimisation du schéma de prélèvement pour les études de bioéquivalence. Therapie 1993; 48: 7-13.
112. Aarons L, Balant LP, Mentre F et al. Population approaches in drug development: report on an expert meeting to discuss population pharmacokinetic/pharmacodynamic software. Eur J Clin Pharmacol 1994; 46: 383-391
113. Maddix DS, Warner L. Do we need an intravenous fluoroquinolone? West J Med 1992; 157: 55-59.
114. Just PM. Overview of the fluoroquinolone antibiotics. Pharmacotherapy 1993; 13 (2 Pt 2): 4-17.
115. Hadjhadj F. Les anti-histaminiques H2 disponibles sous forme orale et injectable: pharmacocinétique et relais d'administration de la voie parentérale par la voie orale. Thèse no 842303 pour le diplôme d'état de docteur en Pharmacie, Lyon, 1993.